CNTX
Income statement / Annual
Last year (2024), Context Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Context Therapeutics Inc.'s net income was -$26.73 M.
See Context Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$12,044.00
|
$9,268.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$12,044.00
|
-$9,268.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$22.70 M
|
$17.78 M
|
$7.09 M
|
$3.81 M
|
$1.64 M
|
$2.41 M
|
| General & Administrative Expenses |
$7.22 M
|
$7.29 M
|
$7.79 M
|
$3.63 M
|
$930,667.00
|
$2.97 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.22 M
|
$7.29 M
|
$7.79 M
|
$3.63 M
|
$930,667.00
|
$2.97 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$2,004.00
|
$123,872.00
|
$9.88 M
|
$93,365.00
|
| Operating Expenses |
$29.92 M
|
$25.07 M
|
$14.88 M
|
$7.44 M
|
$2.57 M
|
$5.38 M
|
| Cost And Expenses |
$0.00
|
$25.07 M
|
$14.88 M
|
$7.44 M
|
$2.57 M
|
$5.38 M
|
| Interest Income |
$3.20 M
|
$1.16 M
|
$547,268.00
|
$64.24
|
$661.22
|
$1,100.39
|
| Interest Expense |
$0.00
|
$0.00
|
$547,268.00
|
$64,240.00
|
$661,224.00
|
$1.10 M
|
| Depreciation & Amortization |
$0.00
|
$12,044.00
|
$9,268.00
|
-$3.09 M
|
$2.57 M
|
$5.38 M
|
| EBITDA |
-$26.67 M |
-$25.06 M |
-$14.83 M |
-$10.53 M |
$0.00 |
$0.00 |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$3.20 M
|
$1.11 M
|
$545,264.00
|
$68,949.00
|
$9.22 M
|
-$1.01 M
|
| Income Before Tax |
-$26.73 M
|
-$23.96 M
|
-$14.84 M
|
-$10.46 M
|
$6.64 M
|
-$6.38 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$545,264.00
|
-$3.02 M
|
$661,224.00
|
$1.10 M
|
| Net Income |
-$26.73 M
|
-$23.96 M
|
-$14.29 M
|
-$7.43 M
|
$6.64 M
|
-$7.48 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.46 |
-1.5 |
-0.9 |
-0.47 |
0.61 |
-0.68 |
| EPS Diluted |
-0.46 |
-1.5 |
-0.9 |
-0.47 |
0.61 |
-0.68 |
| Weighted Average Shares Out |
$58.42 M
|
$15.97 M
|
$15.97 M
|
$15.97 M
|
$10.96 M
|
$10.96 M
|
| Weighted Average Shares Out Diluted |
$58.42 M
|
$15.97 M
|
$15.97 M
|
$15.97 M
|
$10.96 M
|
$10.96 M
|
| Link |
|
|
|
|
|
|
